AMO Pharma Limited

AMO Pharma Limited is a biopharmaceutical company focused on developing innovative treatments for serious genetic disorders, targeting unmet medical needs through its investigational therapies. AMO Pharma Limited specializes in the development of biopharmaceutical products aimed at addressing rare genetic disorders. Founded by Ibraheem Mahmood, the company is headquartered in London, UK. In June 2015, AMO Pharma raised USD 25 mn in funding from Woodford Patient Capital Trust, bringing the total amount raised to USD 25 mn and valuing the company at USD 57.

06 mn post-money. AMO Pharma specializes in innovative biopharmaceutical products designed to treat serious and debilitating diseases, particularly rare genetic disorders. The company’s pipeline includes investigational therapies such as AMO-01, AMO-02, and AMO-04, targeting conditions like Phelan-McDermid Syndrome, Congenital Myotonic Dystrophy, and Rett Syndrome. Its products are aimed at healthcare providers, hospitals, and specialty clinics globally, focusing on regions with high demand for orphan disease treatments.

AMO Pharma's revenue model revolves around the development and commercialization of its investigational therapies through direct sales to healthcare providers and partnerships with pharmaceutical distributors. The company engages in B2B transactions, supplying hospitals and specialty clinics that treat patients with rare diseases. The EBITDA for the most recent year, 2021, was reported at USD -11. 96 mn, reflecting the company's focus on advancing its product pipeline and establishing valuable partnerships for accessibility to its treatments.

AMO Pharma plans to leverage the USD 25 mn raised in June 2015 to support the advancement of its clinical-stage therapies, including upcoming launches in new markets targeting conditions associated with rare diseases. The company is working to expand its presence in regions where there is a significant need for treatments for orphan diseases. The strategic use of recent funding will facilitate the development of new products and support market entry initiatives, enhancing their therapeutic offerings globally.